Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Durability of Triple Combination Therapy Versus Stepwise Addition Therapy in Patients With New-Onset T2DM: 3-Year Follow-up of EDICT
Muhammad Abdul‐Ghani, Curtiss Puckett, John M. Adams, et al.
Diabetes Care (2020) Vol. 44, Iss. 2, pp. 433-439
Open Access | Times Cited: 47

Showing 1-25 of 47 citing articles:

Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Melanie J. Davies, Vanita R. Aroda, Billy S. Collins, et al.
Diabetes Care (2022) Vol. 45, Iss. 11, pp. 2753-2786
Open Access | Times Cited: 1176
Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Melanie J. Davies, Vanita R. Aroda, Billy S. Collins, et al.
Diabetologia (2022) Vol. 65, Iss. 12, pp. 1925-1966
Open Access | Times Cited: 687
American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan—2022 Update
Lawrence Blonde, Guillermo E. Umpierrez, Sarah Reddy, et al.
Endocrine Practice (2022) Vol. 28, Iss. 10, pp. 923-1049
Open Access | Times Cited: 327
American Association of Clinical Endocrinology Consensus Statement: Comprehensive Type 2 Diabetes Management Algorithm – 2023 Update
Susan L. Samson, Priyathama Vellanki, Lawrence Blonde, et al.
Endocrine Practice (2023) Vol. 29, Iss. 5, pp. 305-340
Open Access | Times Cited: 213
Drug Therapies for Diabetes
Roni Weinberg Sibony, Omri Segev, Saar Dor, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 24, pp. 17147-17147
Open Access | Times Cited: 31
Managing insulin resistance: the forgotten pathophysiological component of type 2 diabetes
Muhammad Abdul-Ghani, Pietro Maffei, Ralph A. DeFronzo
The Lancet Diabetes & Endocrinology (2024) Vol. 12, Iss. 9, pp. 674-680
Closed Access | Times Cited: 15
An Update on the Current and Emerging Use of Thiazolidinediones for Type 2 Diabetes
Rosaria Vincenza Giglio, Νικόλαος Παπάνας, Ali A. Rizvi, et al.
Medicina (2022) Vol. 58, Iss. 10, pp. 1475-1475
Open Access | Times Cited: 37
Combination therapy with pioglitazone/exenatide/metformin reduces the prevalence of hepatic fibrosis and steatosis: The efficacy and durability of initial combination therapy for type 2 diabetes (EDICT)
Olga Lavynenko, Muhammad Abdul‐Ghani, Mariam Alatrach, et al.
Diabetes Obesity and Metabolism (2022) Vol. 24, Iss. 5, pp. 899-907
Closed Access | Times Cited: 28
Efficacy and tolerability of initial triple combination therapy with metformin, dapagliflozin and saxagliptin compared with stepwise add‐on therapy in drug‐naïve patients with type 2 diabetes (TRIPLE‐AXEL study): A multicentre, randomized, 104‐week, open‐label, active‐controlled trial
Nam Hoon Kim, Jun Sung Moon, Yong‐ho Lee, et al.
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. 9, pp. 3642-3652
Open Access | Times Cited: 4
Long-term effectiveness and safety of quadruple combination therapy with empagliflozin versus dapagliflozin in patients with type 2 diabetes: 3-year prospective observational study
Eu Jeong Ku, Dong‐Hwa Lee, Hyun Jeong Jeon, et al.
Diabetes Research and Clinical Practice (2021) Vol. 182, pp. 109123-109123
Open Access | Times Cited: 25
Pioglitazone with SGLT2 inhibitors or GLP-1 receptor agonists in patients with type 2 diabetes and non-alcoholic fatty liver disease: could the combinations of an old friend with new players yield better outcomes?
Georgios S. Papaetis, Michalis Picolos, Anastasia Sacharidou
Archives of Medical Science - Atherosclerotic Diseases (2025) Vol. 10, Iss. 1, pp. 1-15
Open Access
Understanding the peroxisome proliferator-activated receptor gamma (PPAR-γ) role in periodontitis and diabetes mellitus: A molecular perspective
Ingra Gagno Nicchio, Thamiris Cirelli, Lucas César da Costa Quil, et al.
Biochemical Pharmacology (2025), pp. 116908-116908
Closed Access
From Glucose Control to Multifaceted Benefits: The Rise of Modern Sulphonylureas in Diabetes Care
Dina Shrestha, Atul Dhingra, Santosh Shakya, et al.
Current Diabetes Reports (2025) Vol. 25, Iss. 1
Closed Access
3. BLOOD GLUCOSE-LOWERING THERAPIES – NON-INSULIN OPTIONS FOR TYPE 2 DIABETES
Stephen Colagiuri, Antonio Ceriello
Diabetes Research and Clinical Practice (2025), pp. 112147-112147
Closed Access
Glycemic and non-glycemic benefits of initial triple therapy versus sequential add-on therapy in patients with new-onset diabetes: results from the EDICT study
Muhammad Abdul‐Ghani, Curtiss Puckett, Siham Abdelgani, et al.
BMJ Open Diabetes Research & Care (2025) Vol. 13, Iss. 2, pp. e004981-e004981
Open Access
Treating Type 2 Diabetes With Early, Intensive, Multimodal Pharmacotherapy: Real-World Evidence From an International Collaborative Database
Matthew Anson, Ayesha Malik, Sizheng Steven Zhao, et al.
Journal of Diabetes Research (2024) Vol. 2024, pp. 1-11
Open Access | Times Cited: 3
Intense simplified strategy for newly diagnosed type 2 diabetes in patients with severe hyperglycaemia: multicentre, open label, randomised trial
Liehua Liu, Weijian Ke, Hai Li, et al.
BMJ (2024), pp. e080122-e080122
Open Access | Times Cited: 2
Pioglitazone in diabetic kidney disease: forgotten but not gone
Georgios S. Papaetis
Archives of Medical Science - Atherosclerotic Diseases (2022) Vol. 7, Iss. 1, pp. 78-93
Open Access | Times Cited: 11
Time to reposition sulfonylureas in type 2 diabetes management in Indian context: A pragmatic practical approach
Ashok Kumar Das, Banshi Saboo, Rajeev Chawla, et al.
International Journal of Diabetes in Developing Countries (2023) Vol. 43, Iss. 6, pp. 856-874
Open Access | Times Cited: 5
Incorporating Evidence and Guidelines for Personalized Care of Diabetes and Chronic Kidney Disease
Joshua J. Neumiller, Radica Z. Alicic, Katherine R. Tuttle
Seminars in Nephrology (2023) Vol. 43, Iss. 3, pp. 151427-151427
Open Access | Times Cited: 5
Combine and Conquer: With Type 2 Diabetes Polypharmacy Is Essential Not Only to Achieve Glycemic Control but Also to Treat the Comorbidities and Stabilize or Slow the Advancement of Diabetic Nephropathy
David S.H. Bell
Journal of Diabetes Research (2022) Vol. 2022, pp. 1-8
Open Access | Times Cited: 8
AWARE A novel web application to rapidly assess cardiovascular risk in type 2 diabetes mellitus
Cesare Berra, Roberto Manfrini, Marco Mirani, et al.
Acta Diabetologica (2023) Vol. 60, Iss. 9, pp. 1257-1266
Open Access | Times Cited: 4
Initial Combination Therapy in Type 2 Diabetes
Ji Yoon Kim, Nam Hoon Kim
Endocrinology and Metabolism (2023) Vol. 39, Iss. 1, pp. 23-32
Open Access | Times Cited: 4
Oral Glucose‐Lowering Agents
Clifford J. Bailey, Andrew J. Krentz
(2024), pp. 492-519
Closed Access | Times Cited: 1
Acute pharmacodynamic responses to sitagliptin: Drug‐induced increase in early insulin secretion in oral glucose tolerance test
Amber L. Beitelshees, Elizabeth A. Streeten, Zhinous Shahidzadeh Yazdi, et al.
Clinical and Translational Science (2024) Vol. 17, Iss. 5
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top